Peptide Comparison
AdipotidevsAOD-9604
A targeted fat-destroying peptide that works like a smart missile, cutting off blood supply to fat cells and causing rapid weight loss in primate studies.
A modified fragment of human growth hormone that targets fat cells for breakdown without affecting blood sugar or muscle growth—your metabolism's precision tool.
At a Glance
Quick
comparison
Dose Range
Adipotide
0.1–0.43 mg/kg
AOD-9604
250–500 mcg
Frequency
Adipotide
Once daily
AOD-9604
Once daily
Administration
Adipotide
Subcutaneous injection
AOD-9604
Subcutaneous injection
Cycle Length
Adipotide
4-6 weeks
AOD-9604
8-12 weeks
Onset Speed
Adipotide
Moderate (1-2 weeks)
AOD-9604
Gradual (3-4 weeks)
Evidence Level
Adipotide
Strong preclinical (extensive animal studies)
AOD-9604
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Fat Elimination
Metabolic Improvement
Speed of Results
Fat Targeting
Safety Profile
Joint Support
Technical Data
Compound
specifications
Adipotide
Molecular Formula
C111H206N36O28S2
Molecular Weight
2611.41 g/mol
Half-Life
~24 hours
Bioavailability
High (subcutaneous injection)
CAS Number
859216-15-2
AOD-9604
Molecular Formula
C78H123N23O23S2
Molecular Weight
1815.1 g/mol
Half-Life
~3-4 minutes (plasma)
Bioavailability
High (subcutaneous)
CAS Number
221231-10-3
Protocols
Dosing
tiers
Adipotide
AOD-9604
Applications
Best
suited for
Adipotide
Targeted White Fat Reduction
Adipotide specifically seeks out and destroys the blood vessels feeding white adipose tissue. Unlike diet or exercise that shrink fat cells, this peptide actually eliminates fat tissue by cutting off its blood supply - a completely unique mechanism.
Stubborn Fat Deposits
Because it targets the vasculature of fat tissue directly, Adipotide may be particularly effective for stubborn fat deposits that resist traditional methods. The peptide homes in on prohibitin receptors found specifically on blood vessels supplying fat tissue.
Improving Insulin Resistance
Primate studies showed remarkable improvements in insulin sensitivity - treated monkeys used about 50% less insulin after treatment. This makes it interesting for research into obesity-related metabolic dysfunction.
Research Applications
As a pioneering vascular-targeting peptide, Adipotide represents a new class of potential therapeutics. Its unique mechanism of targeting specific tissue vasculature has implications beyond obesity research.
AOD-9604
Targeted Fat Loss
AOD-9604 shines when you want to target stubborn fat deposits. It works by mimicking how growth hormone breaks down fat, but without the side effects of actual HGH. Think of it as a smart missile that targets fat cells specifically.
Body Recomposition
Perfect for those who want to lose fat while maintaining muscle. Unlike many fat loss compounds, AOD-9604 doesn't affect muscle tissue or mess with your blood sugar levels—it's laser-focused on fat metabolism.
Metabolic Enhancement
Ideal for boosting your metabolism naturally. AOD-9604 increases fat oxidation (your body's ability to burn fat for fuel) without the jittery stimulant effects of caffeine or other thermogenics.
Joint Health Support
Emerging research shows AOD-9604 may help repair cartilage and support joint health. Studies in osteoarthritis models show it can reduce cartilage damage, making it a dual-purpose peptide for active individuals.
Metabolically Safe Fat Loss
Unlike many weight loss compounds, AOD-9604 doesn't raise blood sugar, doesn't affect insulin, and doesn't stimulate cell growth. It's one of the gentlest approaches to enhancing fat metabolism available.
Safety Profile
Side
effects
Adipotide
Common
- Elevated Serum Creatinine
- Proteinuria
- Glucosuria
- Reduced Appetite
Uncommon
- Mild Dehydration
- Injection Site Reactions
Serious
- Renal Tubular Dysfunction
AOD-9604
Common
- Injection site reactions
- Mild headache
- Flushing or warmth
Uncommon
- Fatigue
- Dizziness
Serious
- Allergic reaction
Research Status
Safety
& evidence
Adipotide
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
Adipotide has been extensively studied in mice, rats, and three species of primates with consistent results. The primary safety concern is dose-dependent kidney effects, which were reversible upon stopping treatment in all studies. No cardiovascular, neurological, or hepatic adverse events were observed. The compound shows remarkable selectivity - lean animals given the same doses experienced no weight loss, suggesting it specifically targets excess fat tissue.
Contraindications
- xKidney disease or impaired renal function
- xPregnancy or breastfeeding
- xActive infections or compromised immune system
- xHistory of severe allergic reactions to peptides
- xDehydration or conditions affecting fluid balance
AOD-9604
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Not FDA approved
Safety Overview
AOD-9604 has been studied in multiple human clinical trials involving thousands of participants. The safety profile is notably clean—it doesn't affect blood sugar, insulin levels, or cause the typical side effects of growth hormone. Phase 2 trials showed it was well-tolerated even at doses higher than typically used. The most common side effects are mild and injection-site related.
Contraindications
- xPregnancy or breastfeeding
- xActive cancer or history of cancer
- xKnown allergy to growth hormone-derived peptides
- xChildren and adolescents
Decision Guide
Which is
right for you?
Choose Adipotide if...
- Targeted fat reduction
- Improving insulin resistance
- Reducing stubborn white adipose tissue
- Research into vascular-targeted therapies
Choose AOD-9604 if...
- Fat loss
- Body composition improvement
- Metabolic support
- Joint health support